{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T21:19:23Z","timestamp":1771535963175,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2009,12,15]],"date-time":"2009-12-15T00:00:00Z","timestamp":1260835200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1007\/s00702-009-0344-4","type":"journal-article","created":{"date-parts":[[2009,12,14]],"date-time":"2009-12-14T02:56:07Z","timestamp":1260759367000},"page":"333-342","source":"Crossref","is-referenced-by-count":25,"title":["Direct switch from levodopa\/benserazide or levodopa\/carbidopa to levodopa\/carbidopa\/entacapone in Parkinson\u2019s disease patients with wearing-off: efficacy, safety and feasibility\u2014an open-label, 6-week study"],"prefix":"10.1007","volume":"117","author":[{"given":"Karla","family":"Eggert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d6rjan","family":"Skogar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khaled","family":"Amar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liisa","family":"Luotonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikko","family":"Kuoppam\u00e4ki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mika","family":"Leinonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Nissinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Oertel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,12,15]]},"reference":[{"key":"344_CR1","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1136\/jnnp.74.8.1071","volume":"74","author":"DJ Brooks","year":"2003","unstructured":"Brooks DJ, Sagar H (2003) Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson\u2019s disease: a randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry 74:1071\u20131079","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"344_CR2","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1159\/000086479","volume":"53","author":"DJ Brooks","year":"2005","unstructured":"Brooks DJ, Agid Y, Eggert K, Widner H, Ostergaard K, Holopainen A, The TC-INIT Study Group (2005) Treatment of end-of-dose wearing-off in Parkinson\u2019s disease: Stalevo\u00ae (Levodopa\/Carbidopa\/Entacapone) and levodopa\/DDCI given in combination with Comtess\u00ae\/Comtan\u00ae (Entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa\/DDCI treatment. Eur Neurol 53:197\u2013202","journal-title":"Eur Neurol"},{"key":"344_CR3","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s11948-004-0071-z","volume":"10","author":"R Fuente-Fernandez de la","year":"2004","unstructured":"de la Fuente-Fernandez R, Stoessl AJ (2004) The biochemical bases of the placebo effect. Sci Eng Ethics 10:143\u2013150","journal-title":"Sci Eng Ethics"},{"key":"344_CR4","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.biopsych.2003.11.019","volume":"56","author":"R Fuente-Fernandez de la","year":"2004","unstructured":"de la Fuente-Fernandez R, Schulzer M, Stoessl AJ (2004) Placebo mechanisms and reward circuitry: clues from Parkinson\u2019s disease. Biol Psychiatry 56:67\u201371","journal-title":"Biol Psychiatry"},{"key":"344_CR5","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, van Hilten JJ, LaPelle N (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23:2129\u20132170","journal-title":"Mov Disord"},{"key":"344_CR6","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s00702-004-0190-3","volume":"111","author":"A Gordin","year":"2004","unstructured":"Gordin A, Kaakkola S, Teravainen H (2004) Clinical advantages of COMT inhibition with entacapone\u2013\u2013a review. J Neural Transm 111:1343\u20131363","journal-title":"J Neural Transm"},{"key":"344_CR7","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00702-004-0184-1","volume":"112","author":"W Koller","year":"2005","unstructured":"Koller W, Guarnieri M, Hubble J, Rabinowicz AL, Silver D (2005) An open-label evaluation of the tolerability and safety of Stalevo\u00ae (carbidopa, levodopa and entacapone) in Parkinson\u2019s disease patients experiencing wearing-off. J Neural Transm 112:221\u2013230","journal-title":"J Neural Transm"},{"key":"344_CR8","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00228-009-0622-y","volume":"65","author":"M Kuoppam\u00e4ki","year":"2009","unstructured":"Kuoppam\u00e4ki M, Korpela K, Marttila R, Kaasinen V, Hartikainen P, Lyytinen J, Kaakkola S, H\u00e4nninen J, L\u00f6yttyniemi E, Kailaj\u00e4rvi M, Ruokoniemi P, Ellm\u00e9n J (2009) Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa\/carbidopa\/entacapone and levodopa\/carbidopa when administered four- or five-times daily. Eur J Clin Pharmacol 65:443\u2013455","journal-title":"Eur J Clin Pharmacol"},{"key":"344_CR9","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1468-1331.2007.02047.x","volume":"15","author":"G Linazasoro","year":"2008","unstructured":"Linazasoro G, Kulisevsky J, Hernandez B (2008) Should levodopa dose be reduced when switched to stalevo? Eur J Neurol 15:257\u2013261","journal-title":"Eur J Neurol"},{"key":"344_CR10","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00702-006-0442-5","volume":"113","author":"T Muller","year":"2006","unstructured":"Muller T, Erdmann C, Muhlack S, Bremen D, Przuntek H, Goetze O, Woitalla D (2006a) Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa\/carbidopa with and without entacapone in patients with Parkinson\u2019s disease. J Neural Transm 113:1441\u20131448","journal-title":"J Neural Transm"},{"key":"344_CR11","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/mds.20717","volume":"21","author":"T Muller","year":"2006","unstructured":"Muller T, Erdmann C, Muhlack S, Bremen D, Przuntek H, Woitalla D (2006b) Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels. Mov Disord 21:332\u2013336","journal-title":"Mov Disord"},{"key":"344_CR12","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/mds.20243","volume":"19","author":"CW Olanow","year":"2004","unstructured":"Olanow CW, Agid Y, Mizuno Y, Albanese A, Bonuccelli U, Damier P, De Yebenes J, Gershanik O, Guttman M, Grandas F, Hallett M, Hornykiewicz O, Jenner P, Katzenschlager R, Langston WJ, LeWitt P, Melamed E, Mena MA, Michel PP, Mytilineou C, Obeso JA, Poewe W, Quinn N, Raisman-Vozari R, Rajput AH, Rascol O, Sampaio C, Stocchi F (2004) Levodopa in the treatment of Parkinson\u2019s disease: current controversies. Mov Disord 19:997\u20131005","journal-title":"Mov Disord"},{"key":"344_CR13","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/ana.410420511","volume":"42","author":"Parkinson Study Group","year":"1997","unstructured":"Parkinson Study Group (1997) Entacapone improves motor fluctuations in levodopa-treated Parkinson\u2019s disease patients. Ann Neurol 42:747\u2013755","journal-title":"Ann Neurol"},{"key":"344_CR14","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1034\/j.1600-0404.2002.1o174.x","volume":"105","author":"WH Poewe","year":"2002","unstructured":"Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M (2002) Efficacy and safety of entacapone in Parkinson\u2019s disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurologica Scand 105:245\u2013255","journal-title":"Acta Neurologica Scand"},{"key":"344_CR15","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1212\/WNL.51.5.1309","volume":"51","author":"UK Rinne","year":"1998","unstructured":"Rinne UK, Larsen JP, Siden A, Worm-Petersen J, The Nomecomt Study Group (1998) Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Neurology 51:1309\u20131314","journal-title":"Neurology"},{"key":"344_CR16","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/01.WNF.0000232277.68501.08","volume":"29","author":"M Stacy","year":"2006","unstructured":"Stacy M, Hauser R, Oertel W, Schapira A, Sethi K, Stocchi F, Tolosa E (2006) End-of-dose wearing off in Parkinson disease: a 9-question survey assessment. Clin Neuropharmacol 29:312\u2013321","journal-title":"Clin Neuropharmacol"},{"key":"344_CR17","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1517\/14656566.7.10.1399","volume":"7","author":"F Stocchi","year":"2006","unstructured":"Stocchi F (2006) The levodopa wearing-off phenomenon in Parkinson\u2019s disease: pharmacokinetic considerations. Expert Opin Pharmacother 7:1399\u20131407","journal-title":"Expert Opin Pharmacother"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-009-0344-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00702-009-0344-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-009-0344-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T00:25:17Z","timestamp":1559089517000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00702-009-0344-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12,15]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["344"],"URL":"https:\/\/doi.org\/10.1007\/s00702-009-0344-4","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12,15]]}}}